Skip to main content
Top
Published in: World Journal of Surgery 2/2011

01-02-2011

Metachronous Cancer in the Stomach Remnant

Author: Christos S. Katsios

Published in: World Journal of Surgery | Issue 2/2011

Login to get access

Excerpt

Despite a rapid drop in the incidence of gastric cancer in the United States, northwestern Europe, and other countries, gastric cancer continues to be a major health problem in Japan, Korea, China, and other Asian countries. In an effort to improve survival and cure rates, Japan has established endoscopic screening programs. As a result, more than 50% of patients with early gastric cancer are diagnosed and so have an excellent prognosis. Appropriate surgery alone or endoscopic submucosal dissection (ESD) after meeting certain criteria not only improve cure rates but also provide a good quality of life. Despite the relatively low risk of metachronous distant metastasis, however, the risk of local recurrence in the stomach remnant after limited surgery or ESD for early gastric cancer may be substantial. …
Literature
1.
go back to reference Nozaki I, Nasu J, Kubo Y, Tanada M, Nishimura R, Kurita A (2010) Risk factors for metachronous gastric cancer in the remnant stomach after early cancer surgery. World J Surg 34:1548–1554CrossRefPubMed Nozaki I, Nasu J, Kubo Y, Tanada M, Nishimura R, Kurita A (2010) Risk factors for metachronous gastric cancer in the remnant stomach after early cancer surgery. World J Surg 34:1548–1554CrossRefPubMed
2.
go back to reference Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697 Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697
3.
go back to reference Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545CrossRefPubMed Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545CrossRefPubMed
4.
go back to reference Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMed Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMed
5.
go back to reference Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMed Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMed
6.
go back to reference Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMed Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMed
7.
go back to reference Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMed Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMed
8.
go back to reference Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17 CrossRefPubMed Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17 CrossRefPubMed
9.
go back to reference Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043CrossRefPubMed Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043CrossRefPubMed
10.
go back to reference Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128 CrossRefPubMed Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128 CrossRefPubMed
11.
go back to reference Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMed Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMed
12.
go back to reference Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996 Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996
13.
go back to reference Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586 CrossRefPubMed Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586 CrossRefPubMed
14.
go back to reference Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247-250CrossRefPubMed Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247-250CrossRefPubMed
15.
go back to reference Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681.CrossRefPubMed Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681.CrossRefPubMed
Metadata
Title
Metachronous Cancer in the Stomach Remnant
Author
Christos S. Katsios
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 2/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-010-0806-8

Other articles of this Issue 2/2011

World Journal of Surgery 2/2011 Go to the issue